Randomized, Controlled Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study is a randomized controlled trial of oral semaglutide among treatment-seeking
individuals with AUD. We will randomly assign 50 participants to receive semaglutide
(titrated to 7 mg per day) or matched placebo for 8 weeks. Our primary aims are to assess the
safety and tolerability of semaglutide in this population and to evaluate its effects,
relative to placebo, on alcohol cue-elicited craving and alcohol consumption.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)